TrialJournal of gynecologic oncology2021

Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m² versus 40 mg/m² in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial.

Takashi Motohashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.